Endothelin receptor antagonists: A clinical study update

Current Opinion in Cardiovascular, Pulmonary and Renal Investigational Drugs

Volumn 2, Issue 4, 2000, Pages 339-344

  Wu Wong, J R ^a   Padley, R ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Clinical studies; Endothelin; Receptor antagonists

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 2 BUTYL 7 [2 (2 CARBOXYPROPYL ) 4 METHOXYPHENYL] 5 (3,4 METHYLENEDIOXYPHENYL)CYCLOPENTENO[1,2 B]PYRIDINE; 27 O 3 [2 (3 CARBOXYACRYLOYLAMINO) 5 HYDROXYPHENYL]ACRYLOYLOXY MYRICERONE; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 [4 [3 (3 METHOXY 5 METHYL 2 PYRAZINYLSULFAMOYL) 2 PYRIDYL]PHENYL] 2,2 DIMETHYLPROPIONIC ACID; ABT 546; ATRASENTAN; BMS 193884; BMS 207940; BOSENTAN; CLAZOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOSPORIN A; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; ENRASENTAN; SITAXSENTAN; TAK 044; TEZOSENTAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZD 2574; ZD 4054;

ACUTE KIDNEY FAILURE; BRAIN ISCHEMIA; CANCER; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE COURSE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; HEART INFARCTION; HUMAN; HYPERTENSION; METABOLIC DISORDER; PROSTATE CANCER; PULMONARY HYPERTENSION; REVIEW; RHINITIS; STROKE; SUBARACHNOID HEMORRHAGE;

EID: 0033837697     PISSN: 14648482     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
2. Cloning and expression of a cDNA encoding an endothelin receptor
3. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor
4. The current endothelin receptor classification: Time for reconsideration?
5. Endothelins: Multifunctional renal peptides
6. Endothelin and isoproterenol counter-regulate cAMP and mitogen-activated protein kinases
7. Endothelin attenuates apoptosis in human smooth muscle cells
8. Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells
9. Endothelin-1 is a potent survival factor for c-myc-dependent apoptosis
10. Endothelin: New discoveries and rapid progress in the clinic
11. The role of endothelin-1 and endothelin receptor antagonists in prostate cancer
12. Biological profile of highly potent novel endothelin antagonists selective for the ET(A) receptor
13. Pharmacological profile of FR139317, a novel, potent, endothelin ET(A) receptor antagonist
14. Endothelin ET(A) and ET(B) mRNA and receptors are expressed by smooth muscle in the human vasculature: Majority of the ET(A) subtype
15. Endothelin receptor antagonism
16. The roles of endothelins in proliferation, apoptosis, and angiogenesis
17. Is endothelin-induced vasoconstriction mediated only by ET(A) receptors in humans?
18. ET(A) receptor-induced constrictor responses to endothelin peptides in human blood vessels in vitro
19. Endothelium-independent vascular relaxation mediating ET(B) receptor in rabbit mesenteric arteries
20. Clearance of circulating endothelin-1 by ET(B) receptors in rats
21. The endothelin ET(B) receptor agonist, IRL 1620, causes vasodilatation and inhibits ex vivo platelet aggregation in the anaesthetised rabbit
22. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer
23. Endothelin-induced apoptosis of A375 human melanoma cells
24. Pharmacology of A-216546: A highly selective antagonist for the type-A endothelin receptor
25. Pharmacological characterization of A-127722: An orally active and highly potent ET(A)-selective receptor antagonist
26. ABT-627, an endothelin (ET)-A selective receptor antagonist in men with hormone refractory prostate cancer (HRPCA): Preliminary phase II results
27. Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ET(A)/ET(B) endothelin receptor antagonist
28. The endothelin-A antagonist LU 135252 suppresses ischemic ventricular extrasystoles and fibrillation in pigs and prevents hypoxic cellular decoupling
29. Therapy for microcirculatory disorders in severe acute pancreatitis: Comparison of delayed therapy with ICAM-1 antibodies and a specific endothelin A receptor antagonist
30. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist
31. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators
32. Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A
33. Ro 61-1790, a new hydrosoluble endothelin antagonist: General pharmacology and effects on experimental cerebral vasospasm
34. Pharmacological characterization of a potent nonpeptide endothelin receptor antagonist, 97-139
35. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist
36. Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism
37. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist
38. Pharmacology of a non-selective ET(A) and ET(B) receptor antagonist, TAK-044 and the inhibition of myocardial infarct size in rats
39. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist
40. New non-peptide endothelin-A receptor antagonists: Synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-,-N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthal-enesulfonamides
41. Endothelin-A blockade attenuates systemic and renal hemodynamic effects of L-NAME in humans
42. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1
43. Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice
44. Targeted and natural (piebaldlethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice